Pembrolizumab/Vibostolimab Co-Formulation — Competitive Intelligence Brief

Pembrolizumab/Vibostolimab Co-Formulation (Pembrolizumab/Vibostolimab Co-Formulation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1/PD-L1 inhibitor. Area: Oncology.

phase 3 PD-1/PD-L1 inhibitor PD-1/PD-L1 Oncology Biologic

Target snapshot

Pembrolizumab/Vibostolimab Co-Formulation (Pembrolizumab/Vibostolimab Co-Formulation) — Merck Sharp & Dohme LLC. Pembrolizumab/Vibostolimab Co-Formulation is a PD-1/PD-L1 inhibitor that works by blocking the PD-1/PD-L1 interaction, thereby enhancing the body's immune response against cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pembrolizumab/Vibostolimab Co-Formulation TARGET	Pembrolizumab/Vibostolimab Co-Formulation	Merck Sharp & Dohme LLC	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1
Pf-06823859	pf-06823859	Pfizer	marketed	Monoclonal Antibody	PD-1/PD-L1
Pf-06865571	pf-06865571	Pfizer	marketed	Monoclonal antibody	PD-1/PD-L1 pathway
Investigational products administration	Investigational products administration	Assistance Publique - Hôpitaux de Paris	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1
HyperAcute-Pancreas Immunotherapy	HyperAcute-Pancreas Immunotherapy	NewLink Genetics Corporation	phase 3	Cancer immunotherapy vaccine combination	Tumor-associated antigens (pancreatic cancer cell surface antigens); PD-1/PD-L1 pathway
Praga formulation	Praga formulation	EMS	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1
SPARC1104 modified dose regimen I	SPARC1104 modified dose regimen I	Sun Pharma Advanced Research Company Limited	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1/PD-L1 inhibitor class)

1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 3 drugs in this class
2. AstraZeneca · 2 drugs in this class
3. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
4. Hanlim Pharm. Co., Ltd. · 1 drug in this class
5. EMD Serono · 1 drug in this class
6. EMS · 1 drug in this class
7. Fujian Cancer Hospital · 1 drug in this class
8. Elixiron Immunotherapeutics (Hong Kong) Ltd. · 1 drug in this class
9. Cellvax Therapeutics Inc · 1 drug in this class
10. Anhui Shi, MD · 1 drug in this class